Biogen Idec executives revealed strong phase 3 clinical trial results for experimental multiple sclerosis drug BG-12, which sent shares of the Weston, Mass.-based company to a 52-week high of $106.99. Shares closed Thursday at $99.70, up 13% over Wednesday's close. Biogen Idec already manufactures MS drugs Tysabri and Avonex at its facility in Research Triangle Park, N.C. Growing sales of both drugs led to the strong financial results for the quarter. If BG-12 proves successful, perhaps Biogen Idec could add a third MS drug to its RTP operations and further strengthen the company's position in MS therapies.
Biogen Idec had signaled earlier this month that it had good news on BG-12. So why all the buzz on BG-12? Avonex is an injectable drug; Tysabri is administered through an intravenous infusion. BG-12 is a pill, and the strong results give Biogen Idec an early lead in the growing market for oral MS drugs, The Wall Street Journal reported.
BG-12 would compete against Gelenya, a pill from Novartis
No head-to-head drug trials have been conducted, but BG-12's initial results show that it appears to be more effective than Laquinimod. Aaron Gal, an analyst at Sanford Bernstein, told Reuters that BG's trial results position the drug candidate well against Laquinimod as well as other oral drugs. We'll know more soon. A second study of BG-12 is planned for later this year.
Want to read more about Biogen Idec? Add it to My Watchlist, which will find all of our Foolish analysis on this stock.
Novartis AG and Teva Pharmaceutical Industries are Motley Fool Global Gains recommendations. The Fool owns shares of Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Generic Drug Stocks to Consider Buying Now
Want to cash in on the pharmaceutical boom? Generic drugs add to the arguments for giving Pfizer, Novartis and Mylan a closer look.
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Here Are the Big Pharma Stocks to Own Based on R&D Spending
Roche, Novartis, Pfizer, Johnson & Johnson, and Merck are investing the heaviest in R&D. That could bode well for these big pharma stocks.